Macitentan denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for macitentan are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Limits Macitentan Quantities — and Why You Can Appeal

Macitentan is an endothelin receptor antagonist used in the management of pulmonary arterial hypertension (PAH). Aetna, like most major insurers, places quantity limits on this medication to align dispensing with standard prescribing intervals. A quantity-limit denial does not mean the drug is not covered — it means the amount requested exceeds what the plan's automated system permits per fill cycle. This is one of the most straightforwardly reversible denial types.

## Why These Denials Are Appealable

Quantity-limit denials are administrative in nature. If your prescriber has documented a clinical reason for the quantity requested — for example, a supply needed to cover a travel period, a dose adjustment under titration, or a regimen that falls within the FDA-approved prescribing label — that documentation is usually sufficient to overturn the denial. Aetna is required under its own plan documents and applicable law to adjudicate appeals fairly and to apply only restrictions that are consistent with the FDA-approved labeling.

## Federal Appeal Framework

You have layered protections:

• Internal appeal: Submit a first-level internal appeal to Aetna within the timeframe stated in your denial letter (typically 180 days for non-grandfathered ACA plans or ERISA plans).
• External review (ACA §2719): If your internal appeal fails, most enrollees in non-grandfathered plans are entitled to an independent external review by an accredited Independent Review Organization (IRO). This right typically must be exercised within four months of the final internal denial.
• ERISA §503 full-and-fair review: If your coverage is through an employer-sponsored plan governed by ERISA, you are entitled to a full-and-fair review of any adverse benefit determination.
• Expedited appeal: If your condition is urgent or your health could be seriously harmed by waiting, request an expedited appeal — insurers must respond within 72 hours.

## Documentation to Gather

• Diagnosis confirmation: Records establishing your PAH diagnosis, functional classification, and current clinical status.
• Prescriber letter: A letter from your pulmonologist or specialist explaining the quantity requested, how it aligns with the FDA-approved prescribing label, and why the requested supply is medically necessary.
• Pharmacy records: Documentation of your current fill history and any gaps caused by the quantity restriction.
• Relevant guidelines: Reference to applicable guidelines from the relevant professional societies (such as pulmonary hypertension specialty organizations) supporting the prescribed regimen.

## Criteria-Mapping Structure

Copy each specific requirement from Aetna's published quantity-limit policy and the FDA-approved prescribing label for macitentan. For each requirement, provide the precise chart fact that satisfies it. For example:

| Policy / Label Requirement | Supporting Chart Documentation | |---|---| | Indication consistent with FDA-approved use | [Diagnosis code, specialist note date] | | Quantity consistent with approved dosing schedule | [Prescriber attestation, label reference] | | Clinical justification for supply requested | [Prescriber letter, travel/titration documentation] |

Presenting your appeal as a direct point-by-point response to each stated criterion gives the reviewer a clear path to approval.